ECL cells of the rat stomach: development of lipofuscin in response to sustained gastrin stimulation.
Ageing cells, especially post-mitotic cells, are known to accumulate pigments, i.e. highly electron-dense material, referred to as ceroid or lipofuscin. This material is formed as a consequence of autophagocytosis and peroxidation of the products undergoing degradation. The present study describes the development of lipofuscin in the ECL cells of the rat stomach. These cells produce and secrete histamine in response to gastrin. They are rich in secretory vesicles, which fuse to form vacuoles in hypergastrinaemic rats. Hypergastrinaemia was induced by continuous infusion of human Leu15-gastrin-17 for 6 days or by daily treatment with omeprazole for 10 weeks. Either treatment caused both vacuoles and lipofuscin bodies to appear in large numbers; the vacuoles disappeared promptly after interruption of the hypergastrinaemia, whereas the lipofuscin bodies remained. Antrectomy-evoked hypogastrinaemia was associated with a reduced number and volume density of lipofuscin bodies. Treatment with alpha-fluoromethylhistidine, an irreversible inhibitor of the histamine-forming enzyme, resulted in depletion of ECL-cell histamine and was found to prevent the omeprazole-evoked formation of vacuoles and lipofuscin. The numbers of both vacuoles and lipofuscin bodies were well-correlated with the serum gastrin concentration, suggesting that gastrin stimulates the development not only of vacuoles but also of lipofuscin, perhaps through enhanced autophagocytosis and/or oxidative stress. Thus, lipofuscin bodies may develop from vacuoles, and both vacuoles and lipofuscin bodies may reflect the efforts of overstimulated ECL cells to cope with the excessive formation of secretory products.
Zhao
C M
CM
Department of Pharmacology, University of Lund, Sölvegatan 10, S-22362 Lund, Sweden.
Chen
D
D
Andersson
K
K
Hâkanson
R
R
D000818:Animals; D016922:Cellular Senescence; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005743:Gastrectomy; D005753:Gastric Mucosa / Q000378:metabolism*; D005755:Gastrins / Q000097:blood / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors; D006801:Humans; D008062:Lipofuscin / Q000096:biosynthesis*; D008297:Male; D008762:Methylhistidines / Q000494:pharmacology; D009853:Omeprazole / Q000494:pharmacology; D018384:Oxidative Stress; D010587:Phagocytosis; D011706:Pyloric Antrum / Q000601:surgery; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000166:cytology / Q000187:drug effects; D013997:Time Factors; D014617:Vacuoles / Q000187:drug effects / Q000378:metabolism
D004791:Enzyme Inhibitors; D005755:Gastrins; D008062:Lipofuscin; D008762:Methylhistidines; C037856:gastrin heptadecapeptide, Leu(15)-; C028309:alpha-fluoromethylhistidine; D006640:Histidine Decarboxylase; D009853:Omeprazole